Hematologic Malignancies Detection Market Report 2026

Hematologic Malignancies Detection Market Overview

• Hematologic Malignancies Detection market size has reached to $3.1 billion in 2025 • Expected to grow to $6.28 billion in 2030 at a compound annual growth rate (CAGR) of 15.1% • Growth Driver: Increasing Prevalence Of Blood Cancer Is Driving The Growth Of The Hematologic Malignancies Detection • Market Trend: Technological Advancement To Drive Innovation In The Hematologic Malignancies Detection • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Hematologic Malignancies Detection Market?

Hematologic malignancy detection refers to identifying cancers that affect the blood, bone marrow, and lymphatic system. Hematologic malignancies include a variety of cancers, such as leukemia, lymphoma, and multiple myeloma. These cancers disrupt the average production and function of blood cells. The main types of hematologic malignancy detection are polymerase chain reaction, immunochemistry, next-generation sequencing, fluorescence in situ hybridization, and others. Polymerase chain reaction (PCR) is a technique used to amplify small amounts of DNA, making it easier to analyze and detect genetic mutations or abnormalities associated with hematologic malignancies. This method is applicable to conditions such as multiple myeloma, myelodysplastic syndrome, leukemia, myeloproliferative neoplasms, lymphoma, and others and caters to various end users, including hospitals, specialty clinics, homecare, and others.

What Is The Hematologic Malignancies Detection Market Growth Forecast?

The hematologic malignancies detection market size is expected to see rapid growth in the next few years. It will grow to $6.28 billion in 2030 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to increasing adoption of liquid biopsy diagnostics, rising investments in precision oncology, expansion of genomic testing programs, growing use of ai-based diagnostic platforms, increasing focus on early and accurate cancer detection. Major trends in the forecast period include increasing adoption of molecular diagnostic techniques, rising use of next generation sequencing in oncology, growing integration of ai in diagnostic interpretation, expansion of early cancer screening programs, enhanced focus on personalized oncology diagnostics.

Global Hematologic Malignancies Detection Market Segmentation

1) By Type: Polymerase Chain Reaction, Immunochemistry, Next Generation Sequencing, Fluorescence In Situ Hybridization 2) By Application: Multiple Myeloma, Myelodysplastic Syndrome, Leukemia, Myeloproliferative Neoplasms, Lymphoma, Other Applications 3) By End-Users: Hospitals, Specialty Clinics, Other End-Users Subsegments: 1) By Polymerase Chain Reaction (PCR): Real-Time PCR (qPCR), Digital PCR, Reverse Transcription PCR (RT-PCR), Nested PCR, Multiplex PCR, PCR-Based Detection Kits 2) By Immunochemistry: Enzyme-Linked Immunosorbent Assay (ELISA), Immunohistochemistry (IHC), Flow Cytometry, Immunofluorescence, Immunohistochemical Staining Kits 3) By Next Generation Sequencing (NGS): Whole Genome Sequencing (WGS), Whole Exome Sequencing (WES), Targeted Sequencing, RNA Sequencing (RNA-Seq), Liquid Biopsy NGS, Next-Generation Sequencing Kits For Hematologic Malignancies 4) By Fluorescence In Situ Hybridization (FISH): Chromosome-Specific FISH Probes, DNA FISH, RNA FISH, Multicolor FISH, FISH-Based Detection Kits For Leukemia And Lymphoma

What Is The Driver Of The Hematologic Malignancies Detection Market?

The increasing prevalence of blood cancer is expected to propel the growth of the hematologic malignancy detection market going forward. Blood cancer is a group of cancers affecting the blood, bone marrow, or lymphatic system, disrupting average blood cell production and function. The prevalence of blood cancer is due to aging populations and improved diagnostic techniques that lead to earlier and more accurate detection. Hematologic malignancy detection is essential for blood cancer treatment as it enables early and accurate diagnosis, allowing for personalized and effective treatment strategies. For instance, in March 2024, according to a Cancer Facts & Figures 2023 report published by the Leukemia & Lymphoma Society, a US-based professional organization company, approximately 437,337 people are living with or remission from leukemia in the US. Further, around 59,610 new cases are expected to be diagnosed in 2024. Therefore, the increasing prevalence of blood cancer is driving the growth of the hematologic malignancy detection market.

Key Players In The Global Hematologic Malignancies Detection Market

Major companies operating in the hematologic malignancies detection market are Thermo Fisher Scientific Inc., Abbott Laboratories Inc., Roche Diagnostics International Ltd., Illumina Inc., Agilent Technologies Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Becton Dickinson and Company, Beckman Coulter Inc., Sysmex Corporation, Adaptive Biotechnologies Corporation, NeoGenomics Laboratories Inc., Invivoscribe Technologies Inc., ArcherDx Inc., Invitae Corporation, Natera Inc., Genetron Health, SOPHiA GENETICS, Guardant Health Inc., Genetica Diagnostics

Global Hematologic Malignancies Detection Market Trends and Insights

Major companies operating in the hematologic malignancy detection market are focusing on developing innovative solutions, such as blood cancer diagnostic tests, to enhance diagnostic accuracy and improve patient outcomes. Blood cancer diagnostic tests are crucial for identifying and confirming the presence of hematologic malignancies, such as leukemia, lymphoma, and multiple myeloma. For instance, in November 2023, Roswell Park Comprehensive Cancer Center, a US-based research and treatment center, launched PanHeme, an advanced blood cancer diagnostic test that utilizes next-generation gene sequencing technology for hematologic malignancy detection. Utilizing next-generation sequencing technology, PanHeme identifies genetic mutations in blood cancers such as leukemia, lymphoma, and multiple myeloma within 72 hours, significantly faster than traditional methods. This rapid turnaround enables personalized treatment plans by allowing healthcare providers to utilize targeted FDA-approved therapies based on specific mutations.

What Are Latest Mergers And Acquisitions In The Hematologic Malignancies Detection Market?

In April 2025, NeoGenomics Inc., a US-based cancer diagnostics company, acquired Pathline for an undisclosed amount. Through this acquisition, NeoGenomics aims to strengthen its commercial presence in the Northeast U.S., broaden access to its comprehensive oncology test menu, and expand its molecular and hematology-oncology testing services. Pathline LLC, is a US-based laboratory that provides certified diagnostic testing services, supporting oncologists, hospitals, and healthcare providers with accurate and high-quality laboratory analyses.

Regional Outlook

North America was the largest region in the hematologic malignancies’ detection market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Hematologic Malignancies Detection Market?

The hematologic malignancy detection market consists of revenues earned by entities by providing services such as diagnostic testing, imaging studies, clinical evaluation, genetic counseling, and monitoring and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The hematologic malignancy detection market also includes sales of products including bone marrow aspiration and biopsy kits, flow cytometers, fluorescence in situ hybridization (FISH), and IHC staining kits. Values in this market are factory gate values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Hematologic Malignancies Detection Market Report 2026?

The hematologic malignancies detection market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the hematologic malignancies detection industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.